Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies (mAb) to bind monospecifically to certain cells or proteins. This may then stimulate the patient’s immune system to attack those cells. It is possible to create a mAb specific to almost any extracellular/ cell surface target. Research and development is underway to create antibodies for diseases (such as rheumatoid arthritis, multiple sclerosis, Alzheimer’s disease, Ebola and different types of cancers). Chimeric antibodies are composed of murine variable regions fused onto human constant regions. Humanized antibodies are produced by grafting murine hypervariable regions on amino acid domains into human antibodies. Human monoclonal antibodies are produced using transgenic mice or phage display libraries by transferring human immunoglobulin genes into the murine genome and vaccinating the transgenic mouse against the desired antigen, leading to the production of appropriate monoclonal antibodies. Murine antibodies have short half-life in vivo, limited penetration into tumor sites and inadequately recruit host effector functions.
The global monoclonal antibody therapeutics market segmentation is based on source type (chimeric and humanized, human, murine, others), therapy type (antibody-directed enzyme prodrug therapy, antibody-drug conjugates, radioimmunotherapy), application (autoimmune diseases, cancer, hematological diseases, infection, ophthalmological diseases, others), and end user (hospitals, private clinics, research institutes).
The global monoclonal antibody therapeutics market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global monoclonal antibody therapeutics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global monoclonal antibody therapeutics market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.
Major players operating in the global monoclonal antibody therapeutics market and included in this report are AbbVie, Inc., Alexion Pharmaceuticals, Amgen, Inc., Bayer Healthcare Pharmaceuticals, Biogen. Inc., Bristol-Myers Squibb Company, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Johnson & Johnson, Merck & Co., Inc., Novartis Pharmaceuticals, Pfizer, Inc., Regeneron Pharmaceuticals, Sanofi, Spectrum Pharmaceuticals, Takeda Pharmaceutical Co., and UCB.